You are here: Industry Insights > Gan & Lee

News List

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18 prnasia
December 07, 2021
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug...
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA) prnasia
October 15, 2021
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies ...
New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association's 81st Scientific Sessions prnasia
July 02, 2021
Gan & Lee Pharmaceuticals Co., Ltd., announced positive Phase 1 clinical trial results at the 81st Scientific Sessions of the American Diabetes Association (ADA), June 25th – 29th.
Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma prnasia
April 07, 2021
announced that the European Medicine Gan & Lee Pharmaceuticals Co., Ltd. Agency (EMA) Committee for Orphan Medicinal Products granted orphan drug designation for the investigational compound GLR2007, for the treatment of glioma.
Gan & Lee Announces New Partnership with International Diabetes Federation prnasia
February 22, 2021
Gan & Lee Pharmaceuticals Co., Ltd. has announced a collaborative partnership with the International Diabetes Federation (IDF) that aims to support their global efforts of promoting diabetes care and prevention worldwide.